Q3 reported revenue of $142.4 million increased 3%Q3 GAAP earnings of $0.08 per diluted share compared to the prior-year period earnings of $0.05 per diluted shareNon-GAAP earnings* of $0.17 per diluted share compared
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report
Q2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted shareNon-GAAP earnings* of $0.22 per diluted share compared
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial
Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS),
Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15 per diluted share
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earnings* of
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain
